[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients

1. AJCC cancer staging manual. 7th edition. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. New York: Springer Verlag; 2010.Search in Google Scholar

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.10.3322/caac.2007320610543Search in Google Scholar

3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.10.1016/j.ejca.2012.12.02723485231Search in Google Scholar

4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr.Search in Google Scholar

5. Schild SE, Tan AD, Wampfler JA, Ross HJ, Yang P, Sloan JA. A new scoring system for predicting survival in patients with non-small cell lung cancer. Cancer Med 2015; 4: 1334-43.10.1002/cam4.479456701826108458Search in Google Scholar

6. McCoach CE, Kelly K. Treatment paradigms in advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2013; 11: 629-39.Search in Google Scholar

7. Van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIa. Chest 2000; 117: 374-79.10.1378/chest.117.2.37410669677Search in Google Scholar

8. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123: 226S-43S.10.1378/chest.123.1_suppl.226SSearch in Google Scholar

9. Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, et al. Induction chemo-therapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. Clin Lung Cancer. 2011; 12: 286-92.10.1016/j.cllc.2011.03.03021729649Search in Google Scholar

10. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33: 3488-515.10.1200/JCO.2015.62.1342501942126324367Search in Google Scholar

11. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 2009; 4: 1148-55.10.1097/JTO.0b013e3181ae280f19546818Search in Google Scholar

12. Noonan K, Tong KM, Laskin J, Zheng YY, Melosky B, Sun S, et al. Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. Clin Oncol (R Coll Radiol) 2015; 27: 505-13.10.1016/j.clon.2015.05.00926095646Search in Google Scholar

13. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response- assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21: 1285-92.10.1200/JCO.2003.07.05412663716Search in Google Scholar

14. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002; 35: 179-87.10.1016/S0169-5002(01)00332-4Search in Google Scholar

15. Grgic A, Yüksel Y, Gröschel A, Schäfers HJ, Sybrecht GW, Kirsch CM, et al. Risk stratification of solitary pulmonary nodules by means of PET using (18) F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging 2010; 37: 1087-94.10.1007/s00259-010-1387-3Search in Google Scholar

16. Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, et al. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol 2014; 48: 361-8.10.2478/raon-2014-0038Search in Google Scholar

17. Olivier A, Petyt G, Cortot A, Scherpereel A, Hossein-Foucher C. Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy. Nucl Med Commun 2014; 35: 908-15.10.1097/MNM.0000000000000145Search in Google Scholar

18. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008 20; 26: 1459-64.10.1200/JCO.2007.14.3628Search in Google Scholar

19. Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 2006; 47: 426-31.Search in Google Scholar

20. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012; 39: 27-38.10.1007/s00259-011-1934-6Search in Google Scholar

21. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non–small-cell lung cancer. Clin Lung Cancer 2012; 13: 52-8.10.1016/j.cllc.2011.05.001Search in Google Scholar

22. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010; 136: 883-9.10.1007/s00432-009-0729-7Search in Google Scholar

23. Giorgetti A, Sorace O, Pisani P, Salvadori PA, Mariani G. Accuracy of Qualitative and Semiquantitative Analysis of 18FDG Positron Emission Tomography Scans in the Evaluation of Primary and Metastatic Lesions. Clin Positron Imaging 2000; 3: 182.10.1016/S1095-0397(00)00094-7Search in Google Scholar

24. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. “ErbB receptors: from oncogenes to targeted cancer therapies”. J Clin Invest 2007; 117: 2051-8.10.1172/JCI32278193457917671639Search in Google Scholar

25. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010; 11: 75-84.10.1016/S1470-2045(09)70160-3Search in Google Scholar

26. Storto G, Nicolai E, Salvatore M. [18F]FDG-PET-CT for early monitoring of tumor response: when and why. Q J Nucl Med Mol Imaging 2009; 53: 167-80.Search in Google Scholar

27. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12.10.1097/JTO.0b013e31815e6d6b18166834Search in Google Scholar

28. Tong AN, Han SR, Yan P, Gong H, Zhao H, Yao H, et al. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer. Med Oncol 2014; 31: 780.10.1007/s12032-013-0780-824326983Search in Google Scholar

29. Lebioda A, Makarewicz R, Małkowski B, Dancewicz M, Kowalewski J, Windorbska W. Measurement of primary tumor volume by PET-CT to evaluate risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes. Rep Pract Oncol Radiother 2013; 18: 76-81.10.1016/j.rpor.2012.11.002386325924416539Search in Google Scholar

30. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, et al. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer 2010; 69: 187-93.10.1016/j.lungcan.2009.10.01519942313Search in Google Scholar